Abbott says data at AACR demonstrate advancements in Cancerguard test

Abbott (ABT) announced it will present new data at the American Association for Cancer Research Annual Meeting 2026 demonstrating continued advancements in its multi-biomarker, multi-cancer early detection (MCED) program supporting the commercially available Cancerguard test. In a prospectively collected case-control study, nearly half of positive cancer signals were driven by methylation alone, 47.1%, with additional detection from protein-only, 7.4%, and combined biomarker signals, 45.5%, supporting broader detection across cancer types and stages, the company stated. “We designed Cancerguard as the first-of-its-kind multi-biomarker test because no one signal tells the whole story,” said Tom Beer, M.D., chief medical officer, multi-cancer early detection, Abbott’s cancer diagnostics business. “By combining biomarkers, we can detect cancer earlier, when it matters most.”